Clinical trial NCT05549362: DiAL Health Research Study
Official title: Dietary Approaches to Longevity and Health
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Aging
Weight Loss
Treatment Adherence
Lead sponsor: Pennington Biomedical Research Center
Sponsor class: OTHER
First posted: 2022-09-22
Enrollment: 90
Sex: ALL
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to conduct a five-arm pilot and feasibility trial in healthy, young individuals without obesity to evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.

Detailed description: Nutritional interventions are one of the most promising non-pharmacological approaches that attenuate aging. Continuous calorie restriction (CR), the most studied intervention, extends lifespan in animals and, in humans, slows biological aging and improves healthspan (e.g., disease risk factors, quality of life). In the largest clinical trial of CR in humans (CALERIE 2), adherence to 25% CR waned to \~12% CR over 2 years, which questions the practicality of such interventions over longer periods. CALERIE 2, however, did not benefit from a more advanced approach, namely a Just-in-Time Adaptive Intervention (JITAI), which tailors and optimizes the intervention for each subject. JITAIs strive to provide individuals with the right type and amount of personalized support when necessary by adapting the intervention delivery to the present adherence, needs and environment of the subject. This is accomplished by the use of mobile health (mHealth) technology (smartphones, sensors) to objectively evaluate intervention adherence in real-time and to adapt intervention delivery to each individual over time. The near real-time collection of ecologically valid and objective data from people in their free-living environment dramatically improves the ability to promote adherence and subject engagement.

Newer approaches, such as time-restricted eating (TRE), where food intake is restricted to less than a 10-hour period of the day, may also benefit aging. Short-term pilot studies of TRE showed that, independent of CR, eating over a 6-hour window that began in the morning significantly improved diabetes and cardiovascular risk factors (healthspan) and biomarkers of primary aging (e.g., autophagy, oxidative stress, nutrient sensing). The long-term feasibility of TRE is unknown, and it is unclear if TRE interventions with JITAI designs enhance intervention feasibility and adherence in the context of healthy aging.

The current trial will examine the feasibility and preliminary efficacy of two CR and two TRE interventions to modulate healthspan and biomarkers of aging in healthy, young (25-45 years) individuals. In a 5-arm pilot and feasibility trial, 90 people without obesity (BMI 22-29.9 kg/m2) will be randomized to either ad libitum Control, Traditional CR, Adaptive CR, Traditional TRE, or Adaptive TRE for 24 weeks (n=18/group) for six months

Eligibility criteria: Inclusion Criteria:

1. Healthy male or non-pregnant pre-menopausal female, 25-45 years of age, inclusive
2. BMI ≥22kg/m2 and \<30kg/m2
3. Screening lab values within normal limits, or deemed not clinically significant
4. Stable body weight (less than ± 2kg) in the past 6 months
5. Regularly wake up between 5-8 AM

Exclusion Criteria

1. History of prior bariatric surgery, active gallstone disease, extensive bowel resection or any disease or condition that seriously affects body weight and/or body composition
2. Regular (daily) use of medications for chronic medical conditions.
3. History or clinical manifestation of:

   1. Significant chronic metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, immune, hepatic, renal, urologic, circadian, sleep disorders, reproduction or other condition that would not be considered 'healthy' in opinion of the investigator
   2. Anemia (Hb \<10 g/dL or hematocrit \< 30)
   3. Diabetes or fasting glucose ≥ 126 mg/dL or HbA1c ≥ 6.5% at screening
   4. Hypertension (Systolic Blood Pressure \>140 mmHg \& Diastolic Blood Pressure \>90 mmHg)
   5. Cancer requiring treatment in the past 5 years (except for non-melanoma skin cancer)
   6. Low Bone mineral density z-score \< -2.0 of the hip (total hip or femoral neck) or lumbar spine (L1-L4)
   7. Depression as determined by the Beck Depression Inventory-II \> 19
   8. Pregnant, postpartum (\< 12 months) or lactating females or attempting to become pregnant in the next 7 months
   9. Current or history (within the past 5 years) of an eating disorder
   10. Asthma or sleep apnea
4. Lifestyle related factors that would confound outcomes:

   1. Non-conventional eating patterns (vegan, paleo, fasting, etc.) and eating duration (\<11 hours per day)
   2. Drug or alcohol abuse (up to 14 drinks a week are allowed) within the past 2 years
   3. Current smoking, vaping or use of tobacco products within the past 6 months
   4. Currently participating or recently engaged (4 consecutive weeks in the past 3 months) in heavy aerobic activity (e.g., jogging, running, or riding fast on a bicycle) ≥ 240 minutes per week or heavy resistance training ≥ 3 times per week that results in heavy breathing and sweating.
   5. Perform overnight shift work \> 1 day/week or plan to cross more than 2 time zones within 1 month of study assessments
5. Unwilling or unable to adhere to the rigors of the protocol or failure to complete the behavioral run-in task (at least 80% compliance)

Primary outcomes:
measure: Intervention satisfaction ratings
timeFrame: 6 months
measure: Percent CR (CR groups only)
timeFrame: 6 months
measure: Percent adherence to TRE (TRE groups only)
timeFrame: 10 days over at least 3 timepoints
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
city: Baton Rouge
country: United States
facility: Pennington Biomedical Research Center
state: Louisiana
Study officials:
References: